Emergent Biosolutions (EBS) Sets New 12-Month High at $64.64

Emergent Biosolutions Inc (NYSE:EBS)’s share price reached a new 52-week high on Friday . The stock traded as high as $64.64 and last traded at $64.70, with a volume of 10270 shares changing hands. The stock had previously closed at $60.94.

EBS has been the subject of several research reports. Argus raised their price objective on shares of Emergent Biosolutions to $70.00 and gave the company an “average” rating in a research report on Tuesday, September 11th. They noted that the move was a valuation call. Cantor Fitzgerald set a $62.00 price objective on shares of Emergent Biosolutions and gave the company a “buy” rating in a research report on Thursday, August 9th. Chardan Capital raised their price objective on shares of Emergent Biosolutions from $53.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, August 3rd. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research report on Tuesday, July 10th. Finally, Cowen restated a “hold” rating and set a $49.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, August 29th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $61.63.

The firm has a market capitalization of $3.01 billion, a P/E ratio of 34.21, a PEG ratio of 1.27 and a beta of 1.25. The company has a current ratio of 5.59, a quick ratio of 4.15 and a debt-to-equity ratio of 0.01.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 EPS for the quarter, topping the consensus estimate of $0.88 by $0.19. Emergent Biosolutions had a net margin of 16.55% and a return on equity of 15.09%. The company had revenue of $220.20 million during the quarter, compared to analysts’ expectations of $208.94 million. During the same period last year, the company posted $0.13 earnings per share. The business’s revenue for the quarter was up 118.5% on a year-over-year basis. equities research analysts expect that Emergent Biosolutions Inc will post 2.37 EPS for the current fiscal year.

In other news, Chairman Fuad El-Hibri sold 15,000 shares of the stock in a transaction that occurred on Monday, July 9th. The shares were sold at an average price of $53.61, for a total value of $804,150.00. Following the completion of the sale, the chairman now directly owns 1,539,993 shares of the company’s stock, valued at $82,559,024.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald Richard sold 7,893 shares of the stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $60.02, for a total transaction of $473,737.86. Following the completion of the sale, the director now directly owns 21,063 shares of the company’s stock, valued at $1,264,201.26. The disclosure for this sale can be found here. Over the last quarter, insiders sold 165,087 shares of company stock valued at $9,597,369. Corporate insiders own 16.50% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Stratos Wealth Partners LTD. purchased a new stake in shares of Emergent Biosolutions in the first quarter worth approximately $134,000. PNC Financial Services Group Inc. lifted its position in shares of Emergent Biosolutions by 108.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 1,482 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Emergent Biosolutions in the first quarter worth approximately $171,000. Financial Gravity Wealth Inc. purchased a new stake in shares of Emergent Biosolutions in the first quarter worth approximately $190,000. Finally, Sei Investments Co. lifted its position in shares of Emergent Biosolutions by 5,992.1% in the first quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 3,775 shares in the last quarter. 83.01% of the stock is owned by institutional investors and hedge funds.

About Emergent Biosolutions (NYSE:EBS)

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Further Reading: Book Value Per Share – BVPS

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply